COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 715
[108] Shevach EM. Mechanisms of foxp3+ T regulatory
cell-mediated suppression. Immunity. 2009;30(5):636-645.
[109] Mills KH. Regulatory T cells: friend or foe in immunity to
infection? Nat Rev Immunol. 2004;4(11):841-855.
[110] Shevach EM. Mechanisms of foxp3+ T regulatory
cell-mediated suppression. Immunity. 2009;30(5):636-645.
[111] Vojdani A. A comprehensive approach to assessing immune
status using lymphocyte subset analysis. Clin Rev Allergy Immunol.
2014;46(3):223-230.
[112] Maecker HT, McCoy JP, Nussenblatt R. Standardizing
immunophenotyping for the Human Immunology Project. Nat Rev
Immunol. 2012;12(3):191-200.
[113] Wahren-Herlenius M, Dörner T. Immunopathogenic
mechanisms of systemic autoimmune disease. Lancet.
2013;382(9894):819-831.
[114] Theofilopoulos AN, Kono DH, Baccala R. The multiple
pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724.
[115] Tsokos GC. Systemic lupus erythematosus. N Engl J Med.
2011;365(22):2110-2121.
[116] Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as
therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):317-325.
[117] McInnes IB, Schett G. The pathogenesis of rheumatoid
arthritis. N Engl J Med. 2011;365(23):2205-2219.
[118] Firestein GS, McInnes IB. Immunopathogenesis of
Rheumatoid Arthritis. Immunity. 2017;46(2):183-196.
[119] Dendrou CA, Fugger L, Friese MA. Immunopathology of
multiple sclerosis. Nat Rev Immunol. 2015;15(9):545-558.
715
